Can-Fite CEO granted 24,000 stock options

Can-Fite BioPharma Ltd. reported that its CEO, CFO and COO, Motti Farbstein, received a grant of options to purchase 24,000 Ordinary Shares on an award basis.

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. reported that its CEO, CFO and COO, Motti Farbstein, received a grant of options to purchase 24,000 Ordinary Shares on an award basis. These options have an exercise price of $2.043 per share and expire on June 4, 2036.

The options will vest in sixteen equal quarterly installments starting on September 4, 2026 and ending on April 6, 2030, contingent on his continued service. Following this grant, Farbstein holds 33,132 options to purchase Ordinary Shares directly.

Insider Trade Summary

Grant/Award: 24,000 shares

Grant/Award 1 txn

Insider Farbstein Motti

Role CEO, CFO and COO

Type	Security	Shares	Price	Value
Grant/Award	Options to Purchase Ordinary Shares	24,000	$0.00	$0.00

Holdings After Transaction: Options to Purchase Ordinary Shares — 33,132 contracts (Direct)

Footnotes (3)

1. F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
2. F2. The options will vest in sixteen equal quarterly installments beginning 09/04/2026 and ending 04/06/2030, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
3. F3. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 5.94, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on June 5, 2026, which was NIS 2.908 = USD 1.00.

Key Figures

Options granted: 24,000 options Exercise price: $2.043 per share Options after grant: 33,132 options +5 more

8 metrics

Options granted 24,000 options Grant of options to purchase Ordinary Shares on June 4, 2026

Exercise price $2.043 per share Exercise price for newly granted options

Options after grant 33,132 options Total options held by reporting person following transaction

Expiration date June 4, 2036 Option expiration for this grant

Vesting start September 4, 2026 First quarterly vesting date for the options

Vesting end April 6, 2030 Final quarterly vesting date for the options

Quarterly installments 16 installments Number of equal quarterly vesting tranches

Underlying shares 24,000 Ordinary Shares Shares underlying the option grant

Key Terms

Options to Purchase Ordinary Shares, exercise price, Section 102 of the Israeli Tax Ordinance, Share Option Plan, +2 more

6 terms

Options to Purchase Ordinary Shares financial

"security_title: Options to Purchase Ordinary Shares"

exercise price financial

"The exercise price of this option, originally denominated in New Israeli Shekels"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Section 102 of the Israeli Tax Ordinance regulatory

"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance"

Share Option Plan financial

"Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan"

vesting financial

"The options will vest in sixteen equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"derivativeTransactionCount: 1, derivative transaction in options"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Can-Fite BioPharma (CANF) report in this Form 4 filing?

Can-Fite BioPharma reported an option grant to its CEO, CFO and COO, Motti Farbstein, for 24,000 options to purchase Ordinary Shares at an exercise price of $2.043, expiring June 4, 2036, as part of his compensation.

How many options were granted to the Can-Fite (CANF) CEO in this transaction?

The CEO received 24,000 options to purchase Ordinary Shares. Each option carries an exercise price of $2.043 per share and represents a right, not an immediate share purchase, with vesting over several years subject to continued service.

What is the exercise price and term of the new Can-Fite (CANF) options?

The options have a $2.043 exercise price and expire on June 4, 2036. This means the executive can buy Ordinary Shares at $2.043 per share up to that expiration date, once the options are vested and exercisable.

When do the newly granted Can-Fite (CANF) options vest for the CEO?

The options vest in sixteen equal quarterly installments beginning September 4, 2026 and ending April 6, 2030. Vesting is conditional on the executive’s continued service with the company at each scheduled vesting date.

How many options does the Can-Fite (CANF) executive hold after this grant?

After this grant, the executive holds 33,132 options to purchase Ordinary Shares directly. This total reflects his derivative position following the award and shows his ongoing equity-based compensation exposure to the company’s stock.

Are there any special tax or plan considerations mentioned for the Can-Fite (CANF) options?

The footnotes reference Israeli tax rules under Section 102, noting that plan-related securities must be registered in a trustee’s name for certain tax benefits, and that options may be issued under the 2003, 2013 and 2023 Share Option Plans.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farbstein Motti

(Last) (First) (Middle)

C/O CAN-FITE BIOPHARMA LTD.

26 BEN GURION STREET

(Street)

RAMAT GAN 5257346

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Can-Fite BioPharma Ltd. [ CANF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, CFO and COO

2a. Foreign Trading Symbol
[CANF.TA]

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(1)(2)	$2.043(3)	06/04/2026		A		24,000		09/04/2026	06/04/2036	Ordinary Shares	24,000	$0	33,132	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.

2. The options will vest in sixteen equal quarterly installments beginning 09/04/2026 and ending 04/06/2030, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

3. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 5.94, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on June 5, 2026, which was NIS 2.908 = USD 1.00.

	/s/ Motti Farbstein	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)